TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immutep Ltd ( (AU:IMM) ) has issued an update.
Immutep Limited announced new data from its AIPAC-003 Phase II trial, which will be presented at the 2025 San Antonio Breast Cancer Symposium. The trial evaluated the combination of eftilagimod alfa (efti) and paclitaxel in heavily pretreated metastatic breast cancer patients, achieving strong objective response rates and immune activation. The study successfully met the FDA’s Project Optimus requirements, establishing 30 mg as the optimal biological dose for efti, which is crucial for ongoing and future clinical programs. This development is strategically important for Immutep’s oncology pipeline, including its global Phase III trial with MSD’s KEYTRUDA® for non-small cell lung cancer.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), with a diversified product portfolio that leverages LAG-3’s ability to modulate the immune response.
Average Trading Volume: 2,176,193
Technical Sentiment Signal: Hold
Current Market Cap: A$448.9M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.